Update to living WHO guideline on drugs for COVID-19

Update orders recommendations by severity of COVID-19, and stratifies patients into those at low, moderate, or high risk for hospitalisation. New recommendations have been added for nirmatrelvir/ritonavir (moderate risk) and for molnupiravir and remdesivir (low/moderate risk).

SPS commentary:

This is the fourteenth version (thirteenth update) of the living guideline. The update also includes new evidence for nirmatrelvir/ritonavir and molnupiravir, supporting existing recommendations for patients at high risk of hospitalisation. The recommendation against ivermectin has been updated with additional trial evidence, and a new recommendation has been made against the antiviral agent VV116.

A rapid recommendations article in the BMJ discusses the updates, and provides a visual summary of the recommendations.

World Health Organization

Resource links:

BMJ